S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.69 (+0.31%)
AAPL   460.42 (+1.85%)
MSFT   208.68 (-0.24%)
FB   261.07 (+0.45%)
GOOGL   1,517.17 (+0.66%)
AMZN   3,166.45 (+0.13%)
NVDA   458.36 (+0.16%)
CGC   17.33 (+0.46%)
BABA   254.12 (-0.42%)
TSLA   1,624.62 (+4.49%)
GE   6.61 (-1.64%)
MU   46.23 (-4.64%)
AMD   81.98 (-0.76%)
T   29.90 (-0.93%)
F   7.02 (-1.27%)
ACB   10.19 (+3.98%)
GILD   68.18 (-0.96%)
NFLX   481.11 (+1.19%)
DIS   130.96 (-0.63%)
BAC   26.28 (-1.68%)
BA   174.72 (-0.41%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.69 (+0.31%)
AAPL   460.42 (+1.85%)
MSFT   208.68 (-0.24%)
FB   261.07 (+0.45%)
GOOGL   1,517.17 (+0.66%)
AMZN   3,166.45 (+0.13%)
NVDA   458.36 (+0.16%)
CGC   17.33 (+0.46%)
BABA   254.12 (-0.42%)
TSLA   1,624.62 (+4.49%)
GE   6.61 (-1.64%)
MU   46.23 (-4.64%)
AMD   81.98 (-0.76%)
T   29.90 (-0.93%)
F   7.02 (-1.27%)
ACB   10.19 (+3.98%)
GILD   68.18 (-0.96%)
NFLX   481.11 (+1.19%)
DIS   130.96 (-0.63%)
BAC   26.28 (-1.68%)
BA   174.72 (-0.41%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.69 (+0.31%)
AAPL   460.42 (+1.85%)
MSFT   208.68 (-0.24%)
FB   261.07 (+0.45%)
GOOGL   1,517.17 (+0.66%)
AMZN   3,166.45 (+0.13%)
NVDA   458.36 (+0.16%)
CGC   17.33 (+0.46%)
BABA   254.12 (-0.42%)
TSLA   1,624.62 (+4.49%)
GE   6.61 (-1.64%)
MU   46.23 (-4.64%)
AMD   81.98 (-0.76%)
T   29.90 (-0.93%)
F   7.02 (-1.27%)
ACB   10.19 (+3.98%)
GILD   68.18 (-0.96%)
NFLX   481.11 (+1.19%)
DIS   130.96 (-0.63%)
BAC   26.28 (-1.68%)
BA   174.72 (-0.41%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.69 (+0.31%)
AAPL   460.42 (+1.85%)
MSFT   208.68 (-0.24%)
FB   261.07 (+0.45%)
GOOGL   1,517.17 (+0.66%)
AMZN   3,166.45 (+0.13%)
NVDA   458.36 (+0.16%)
CGC   17.33 (+0.46%)
BABA   254.12 (-0.42%)
TSLA   1,624.62 (+4.49%)
GE   6.61 (-1.64%)
MU   46.23 (-4.64%)
AMD   81.98 (-0.76%)
T   29.90 (-0.93%)
F   7.02 (-1.27%)
ACB   10.19 (+3.98%)
GILD   68.18 (-0.96%)
NFLX   481.11 (+1.19%)
DIS   130.96 (-0.63%)
BAC   26.28 (-1.68%)
BA   174.72 (-0.41%)
Log in

NASDAQ:ALDXAldeyra Therapeutics Stock Price, Forecast & News

$6.72
+0.05 (+0.75 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.60
Now: $6.72
$6.83
50-Day Range
$4.14
MA: $5.60
$7.46
52-Week Range
$1.48
Now: $6.72
$8.05
Volume11,762 shs
Average Volume758,027 shs
Market Capitalization$200.20 million
P/E RatioN/A
Dividend YieldN/A
Beta2.28
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.
Read More
Aldeyra Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.04 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALDX
CUSIPN/A
Phone781-761-4904

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.72 per share

Profitability

Net Income$-60,830,000.00

Miscellaneous

Employees15
Market Cap$200.20 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$6.72
+0.05 (+0.75 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions

How has Aldeyra Therapeutics' stock price been impacted by Coronavirus?

Aldeyra Therapeutics' stock was trading at $2.79 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALDX stock has increased by 140.9% and is now trading at $6.72.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aldeyra Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aldeyra Therapeutics
.

When is Aldeyra Therapeutics' next earnings date?

Aldeyra Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Aldeyra Therapeutics
.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) announced its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.34) by $0.09.
View Aldeyra Therapeutics' earnings history
.

What price target have analysts set for ALDX?

5 brokers have issued twelve-month price objectives for Aldeyra Therapeutics' stock. Their forecasts range from $15.00 to $33.00. On average, they expect Aldeyra Therapeutics' share price to reach $25.60 in the next twelve months. This suggests a possible upside of 281.0% from the stock's current price.
View analysts' price targets for Aldeyra Therapeutics
.

Has Aldeyra Therapeutics been receiving favorable news coverage?

Headlines about ALDX stock have been trending extremely negative on Thursday, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aldeyra Therapeutics earned a news sentiment score of -4.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
View the latest news about Aldeyra Therapeutics
.

Are investors shorting Aldeyra Therapeutics?

Aldeyra Therapeutics saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 629,100 shares, a decline of 29.0% from the June 15th total of 886,600 shares. Based on an average daily volume of 1,110,000 shares, the short-interest ratio is currently 0.6 days. Approximately 2.4% of the shares of the stock are sold short.
View Aldeyra Therapeutics' Short Interest
.

Who are some of Aldeyra Therapeutics' key competitors?

What other stocks do shareholders of Aldeyra Therapeutics own?

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the following people:
  • Todd C. Brady, M.D., Ph.D., Chief Executive Officer and Director (Age 48)
  • Joshua Reed, Chief Financial Officer (Age 47)
  • David McMullin, Chief Commercial Officer (Age 45)
  • James A. Gow, M.D., Senior Vice President of Clinical Development (Age 53)
  • Stephen G. Machatha, Ph.D., Senior Vice President, Technical Operation (Age 43)

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (2.05%), Woodstock Corp (0.50%), Mesirow Financial Investment Management Inc. (0.31%), Russell Investments Group Ltd. (0.14%), Goldman Sachs Group Inc. (0.12%) and Quantitative Systematic Strategies LLC (0.12%). Company insiders that own Aldeyra Therapeutics stock include Ben Bronstein, David Mcmullin, Jesse I Treu, Joshua Reed, Perceptive Advisors Llc, Richard Douglas and Todd C Brady.
View institutional ownership trends for Aldeyra Therapeutics
.

Which major investors are selling Aldeyra Therapeutics stock?

ALDX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bank of New York Mellon Corp, Algert Global LLC, and Mesirow Financial Investment Management Inc..
View insider buying and selling activity for Aldeyra Therapeutics
.

Which major investors are buying Aldeyra Therapeutics stock?

ALDX stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Quantitative Systematic Strategies LLC, State of Wisconsin Investment Board, Woodstock Corp, Blair William & Co. IL, and Goldman Sachs Group Inc.. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Ben Bronstein, David Mcmullin, Joshua Reed, Perceptive Advisors Llc, Richard Douglas, and Todd C Brady.
View insider buying and selling activity for Aldeyra Therapeutics
.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $6.72.

How big of a company is Aldeyra Therapeutics?

Aldeyra Therapeutics has a market capitalization of $200.20 million. The biotechnology company earns $-60,830,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis. Aldeyra Therapeutics employs 15 workers across the globe.

What is Aldeyra Therapeutics' official website?

The official website for Aldeyra Therapeutics is www.ampliphibio.com.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.